Business
Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update
Completed reverse merger and commenced trading on Nasdaq as JBIO Closed financing, raising approximately $300 million to date, providing cash runway through 2027 Lead candidate JADE101 expected to enter the clinic in second half of 2025, with interim biomarker-rich data expected in first half of 2026 SAN FRANCISCO and VANCOUVER, British Columbia, May 14, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies
About this update from Jade Biosciences, Inc.
[{"type":"image","alt":"Jade Biosciences","displaySize":"","headline":null,"caption":"Jade Biosciences","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":112,"url":"https://media.zenfs.com/en/globenewswire.com/345f7337e814bf11ed72261f2fc78278"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Wo31M4PemuELy9uASaVLHA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/345f7337e814bf11ed72261f2fc78278","width":300,"height":112}},"lazy":false},{"type":"text","content":"Completed reverse merger and commenced trading on Nasdaq as JBIO","length":64,"tagName":"p"},{"type":"text","content":"Closed financing, raising approximately $300 million to date, providing cash runway through 2027","length":96,"tagName":"p"},{"type":"text","content":"Lead candidate JADE101 expected to enter the clinic in second half of 2025, with interim biomarker-rich data expected in first half of 2026","length":139,"tagName":"p"},{"type":"text","content":"SAN FRANCISCO and VANCOUVER, British Columbia, May 14, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced financial results for the quarter ending March 31, 2025, and provided a corporate update.","length":328,"tagName":"p"},{"type":"text","content":"“The start to 2025 marked a defining period for Jade Biosciences as we successfully completed our reverse merger, commenced trading as JBIO on Nasdaq, and closed a significant private financing led by a premier syndicate of healthcare investors,” said Tom Frohlich, Chief Executive Officer of Jade. “With a strong balance sheet, we are well-positioned to advance our pipeline of potentially best-in-class therapies for autoimmune diseases. We’re especially excited to become a clinical-stage company later this year, with JADE101 on track to begin first-in-human studies in the second half of 2025. This represents a meaningful step toward delivering differentiated treatment options for patients living with chronic and underserved autoimmune conditions.”","length":756,"tagName":"p"},{"type":"text","content":"Corporate and Pipeline Updates","length":30,"tagName":"p"},{"type":"text","content":"Corporate","length":9,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Compl...